AstraZeneca (AZN) Stock Forecast & Price Target

Compare

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AZN Analyst Ratings

Moderate Buy

12 Buy

2 Hold

1 Sell

Based on 15 analysts giving stock ratings to

AstraZeneca

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

kr1,802.30

▲(6.08% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is kr1,802.30 with a high forecast of kr2,280.18 and a low forecast of kr1,301.19. The average price target represents a 6.08% change from the last price of kr1,699.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1300":"kr1,300","2281":"kr2,281","1545.25":"kr1,545.3","1790.5":"kr1,790.5","2035.75":"kr2,035.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2280.1786,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr2.28K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1802.2990168575,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr1.80K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1301.188875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr1.30K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1300,1545.25,1790.5,2035.75,2281],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1727,1769.5522,1812.1044,1854.6566,1897.2088,1939.761,1982.3132,2024.8654000000001,2067.4176,2109.9698000000003,2152.522,2195.0742,2237.6264,{"y":2280.1786,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1727,1732.7922320659616,1738.5844641319231,1744.3766961978847,1750.168928263846,1755.9611603298076,1761.7533923957692,1767.5456244617308,1773.3378565276923,1779.130088593654,1784.9223206596153,1790.7145527255768,1796.5067847915384,{"y":1802.2990168575,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1727,1694.245298076923,1661.4905961538461,1628.7358942307692,1595.9811923076923,1563.2264903846153,1530.4717884615384,1497.7170865384614,1464.9623846153845,1432.2076826923076,1399.4529807692306,1366.698278846154,1333.943576923077,{"y":1301.188875,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1441.206,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1415.758,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1532.719,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1610.833,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1459.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1388.375,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1359.575,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1352.623,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1416.679,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1508,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1568,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1554,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1727,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr2,280

Average Price Targetkr1,802

Lowest Price Targetkr1,301

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emmanuel Papadakis

Deutsche Bank

kr1,305.16

Sell

-23.18%

Downside

Reiterated

12/16/25

AstraZeneca (AZN) Gets a Sell from Deutsche Bank

Richard Vosser

J.P. Morgan

kr1,740.21→kr1,988.81

Buy

17.06%

Upside

Reiterated

12/08/25

JPMorgan ups AstraZeneca target, adds to Analyst Focus ListJPMorgan ups AstraZeneca target, adds to Analyst Focus List

Justin Smith

Bernstein

kr2,286.94

Buy

34.61%

Upside

Reiterated

12/04/25

Bernstein Sticks to Their Buy Rating for AstraZeneca (AZN)

Sarita Kapila

Morgan Stanley

kr1,740.06→kr1,926.5

Buy

13.39%

Upside

Reiterated

12/03/25

AstraZeneca: Top Pick in a Growing Pharmaceutical Sector with Promising Pipeline and Resolved Overhangs

Unknown Analyst

HSBC

Not Ranked

HSBC

kr1,349.88→kr1,521.38

Buy

-10.45%

Downside

Reiterated

12/02/25

Seamus Fernandez

Guggenheim

kr1,765.07→kr1,926.66

Buy

13.40%

Upside

Reiterated

12/02/25

AstraZeneca (AZN) Receives a Rating Update from a Top Analyst

Michael Leuchten

Jefferies

kr1,864.51

Buy

9.74%

Upside

Reiterated

12/01/25

AstraZeneca (AZN) Receives a Buy from Jefferies

Sachin Jain

Bank of America Securities

kr1,802.21→kr2,050.79

Buy

20.71%

Upside

Reiterated

11/25/25

AstraZeneca: Strong Growth Potential with Robust Pipeline and Attractive Valuation

Luisa Hector

Berenberg Bank

kr1,802.36

Buy

6.08%

Upside

Reiterated

11/11/25

Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)

Elmar Kraus

DZ BANK AG

Hold

―

Reiterated

11/10/25

AstraZeneca (AZN) Gets a Hold from DZ BANK AG

Matthew Weston

UBS

kr1,765.07

Buy

3.89%

Upside

Reiterated

11/07/25

UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

kr1,884.61→kr1,927

Buy

13.42%

Upside

Reiterated

11/07/25

AstraZeneca (AZN) Gets a Buy from Goldman Sachs

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

kr1,802.21

Buy

6.07%

Upside

Reiterated

11/06/25

Shore Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)

David Evans

Kepler Capital

kr1,404.48

Hold

-17.33%

Downside

Reiterated

10/22/25

Kepler Capital Sticks to Its Hold Rating for AstraZeneca (AZN)

Shirley Chen

Barclays

kr1,740.21

Buy

2.43%

Upside

Reiterated

10/21/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emmanuel Papadakis

Deutsche Bank

kr1,305.16

Sell

-23.18%

Downside

Reiterated

12/16/25

AstraZeneca (AZN) Gets a Sell from Deutsche Bank

Richard Vosser

J.P. Morgan

kr1,740.21→kr1,988.81

Buy

17.06%

Upside

Reiterated

12/08/25

JPMorgan ups AstraZeneca target, adds to Analyst Focus ListJPMorgan ups AstraZeneca target, adds to Analyst Focus List

Justin Smith

Bernstein

kr2,286.94

Buy

34.61%

Upside

Reiterated

12/04/25

Bernstein Sticks to Their Buy Rating for AstraZeneca (AZN)

Sarita Kapila

Morgan Stanley

kr1,740.06→kr1,926.5

Buy

13.39%

Upside

Reiterated

12/03/25

AstraZeneca: Top Pick in a Growing Pharmaceutical Sector with Promising Pipeline and Resolved Overhangs

Unknown Analyst

HSBC

Not Ranked

HSBC

kr1,349.88→kr1,521.38

Buy

-10.45%

Downside

Reiterated

12/02/25

Seamus Fernandez

Guggenheim

kr1,765.07→kr1,926.66

Buy

13.40%

Upside

Reiterated

12/02/25

AstraZeneca (AZN) Receives a Rating Update from a Top Analyst

Michael Leuchten

Jefferies

kr1,864.51

Buy

9.74%

Upside

Reiterated

12/01/25

AstraZeneca (AZN) Receives a Buy from Jefferies

Sachin Jain

Bank of America Securities

kr1,802.21→kr2,050.79

Buy

20.71%

Upside

Reiterated

11/25/25

AstraZeneca: Strong Growth Potential with Robust Pipeline and Attractive Valuation

Luisa Hector

Berenberg Bank

kr1,802.36

Buy

6.08%

Upside

Reiterated

11/11/25

Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)

Elmar Kraus

DZ BANK AG

Hold

―

Reiterated

11/10/25

AstraZeneca (AZN) Gets a Hold from DZ BANK AG

Matthew Weston

UBS

kr1,765.07

Buy

3.89%

Upside

Reiterated

11/07/25

UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

kr1,884.61→kr1,927

Buy

13.42%

Upside

Reiterated

11/07/25

AstraZeneca (AZN) Gets a Buy from Goldman Sachs

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

kr1,802.21

Buy

6.07%

Upside

Reiterated

11/06/25

Shore Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)

David Evans

Kepler Capital

kr1,404.48

Hold

-17.33%

Downside

Reiterated

10/22/25

Kepler Capital Sticks to Its Hold Rating for AstraZeneca (AZN)

Shirley Chen

Barclays

kr1,740.21

Buy

2.43%

Upside

Reiterated

10/21/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

1 Month

xxx

Success Rate

22/35 ratings generated profit

Average Return

+2.57%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.86% of your transactions generating a profit, with an average return of +2.57% per trade.

3 Months

xxx

Success Rate

27/45 ratings generated profit

Average Return

+2.70%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.70% per trade.

1 Year

Matthew WestonUBS

Success Rate

35/37 ratings generated profit

Average Return

+17.26%

reiterated a buy rating 2 months ago

Copying Matthew Weston's trades and holding each position for 1 Year would result in 94.59% of your transactions generating a profit, with an average return of +17.26% per trade.

2 Years

xxx

Success Rate

35/37 ratings generated profit

Average Return

+24.79%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 94.59% of your transactions generating a profit, with an average return of +24.79% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AZN has received 33 Buy Ratings, 2 Hold Ratings, and 6 Sell Ratings. AZN average Analyst price target in the past 3 months is 1,802.30.

Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is kr19.51 with a range of kr17.52 to kr21.76. The previous quarter’s EPS was kr21.94. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is kr142.21B with a range of kr138.44B to kr146.57B. The previous quarter’s sales results were kr140.05B. AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Stock Forecast FAQ

What is SE:AZN’s average 12-month price target, according to analysts?

Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 1,802.30.

What is SE:AZN’s upside potential, based on the analysts’ average price target?

AstraZeneca PLC has 6.08% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AstraZeneca PLC a Buy, Sell or Hold?

AstraZeneca PLC has a consensus rating of Moderate Buy, which is based on 12 buy ratings, 2 hold ratings and 1 sell ratings.

What is AstraZeneca PLC’s share price target?

The average share price target for AstraZeneca PLC is 1,802.30. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr2,280.18 ,and the lowest forecast is kr1,301.19. The average share price target represents 6.08% Increase from the current price of kr1,699.

What do analysts say about AstraZeneca PLC?

AstraZeneca PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of AstraZeneca PLC?

To buy shares of SE:AZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AstraZeneca (AZN) Stock Forecast & Price Target

AZN Analyst Ratings

AZN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AstraZeneca

AZN Analyst Recommendation Trends

AZN Financial Forecast

AZN Earnings Forecast

AZN Sales Forecast

AZN Stock Forecast FAQ

Detailed List of Analyst Forecasts